Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
Tumor Volume and Margin Assessment With ex Vivo 3D-ultrasound After Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Verified date | March 2024 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with biopsy-verified oropharyngeal squamous cell carcinoma or Human Papillomavirus (HPV)-positive unknown primary treated with transoral robotic surgery are included. Immediately post-operatively, freshly resected specimens are examined with ex vivo 3D ultrasound (US). Ex vivo 3D US will be used to match US slices of the specimen with corresponding histopathology slices. The US slices will be reviewed by a panel of head and neck surgeons blinded to histopathology. The primary aim is to explore perioperative ex vivo 3D US for oropharyngeal tumor detection, delineation from normal tissue, tumor size and volume, and margin assessment.
Status | Completed |
Enrollment | 15 |
Est. completion date | February 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients surgically treated with transoral robotic surgery for oropharyngeal squamous cell carcinoma or HPV-positive unknown primary. Exclusion Criteria: - No primary tumor found on final histopathology. |
Country | Name | City | State |
---|---|---|---|
Denmark | Dept. of Otorhinolaryngology, Head & Neck Surg, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Makouei F, Agander TK, Ewertsen C, Sondergaard Svendsen MB, Norling R, Kaltoft M, Hansen AE, Rasmussen JH, Wessel I, Todsen T. 3D Ultrasound and MRI in Assessing Resection Margins during Tongue Cancer Surgery: A Research Protocol for a Clinical Diagnostic Accuracy Study. J Imaging. 2023 Aug 28;9(9):174. doi: 10.3390/jimaging9090174. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fresh ex vivo US Tumor detection (blinded to histopathology) | Whether the tumor is visible on US (binary yes/no and 5-point scale from 1: very low certainty - 5 very high certainty) | 5 minutes | |
Primary | Margin assessment (blinded to histopathology) | Whether the tumor is removed with negative margins (yes / no) | 5 minutes | |
Primary | Fresh ex vivo US tumor volume (blinded to histopathology) | Measured with ellipsoid volume (mm^3) | 5 minutes | |
Primary | Fresh ex vivo US margin distance (blinded to histopathology) | Smallest and mean margins measured in mm. | 5 minutes | |
Primary | Fresh ex vivo tumor visible on specimen mecrophoto (blinded to histopathology) | Whether the tumor is visible clinically by inspecting the macrophoto. | 5 minutes | |
Secondary | Fresh ex vivo US tumor volume (unblinded to histopathology) | Measured with ellipsoid volume and segmentation (mm^3) | 1 day | |
Secondary | Formalin-fixed ex vivo US tumor volume (unblinded to histopathology) | Measured with ellipsoid volume and segmentation (mm^3) | 1 day | |
Secondary | Fresh ex vivo US margin distance (unblinded to histopathology) | Smallest and mean margins measured in mm. | 1 day | |
Secondary | Formalin-fixed ex vivo US margin distance (unblinded to histopathology) | Smallest and mean margins measured in mm. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03618134 -
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
|
Phase 1/Phase 2 | |
Recruiting |
NCT03421470 -
Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer
|
Phase 3 | |
Completed |
NCT04572100 -
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Recruiting |
NCT05522881 -
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
|
||
Recruiting |
NCT04222543 -
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
|
Phase 2 | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
Recruiting |
NCT06356272 -
Oropharynx (OPX) Biomarker Trial
|
||
Active, not recruiting |
NCT01874171 -
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
|
Phase 3 | |
Recruiting |
NCT05333523 -
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
|
Phase 3 | |
Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
Active, not recruiting |
NCT03410615 -
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
|
Phase 2 | |
Recruiting |
NCT05268614 -
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05582590 -
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
|
Phase 1 | |
Completed |
NCT02072148 -
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
|
N/A |